Carrera Capital Advisors Acquires Shares of 139,145 Takeda Pharmaceutical Co. $TAK

Carrera Capital Advisors acquired a new stake in Takeda Pharmaceutical Co. (NYSE:TAK) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 139,145 shares of the company’s stock, valued at approximately $2,153,000.

Other large investors also recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its position in Takeda Pharmaceutical by 21.7% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,623 shares of the company’s stock valued at $87,000 after buying an additional 1,003 shares during the period. GAMMA Investing LLC lifted its position in shares of Takeda Pharmaceutical by 22.6% in the 1st quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock worth $105,000 after purchasing an additional 1,296 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Takeda Pharmaceutical in the 1st quarter worth approximately $125,000. Hexagon Capital Partners LLC lifted its position in shares of Takeda Pharmaceutical by 52.9% in the 1st quarter. Hexagon Capital Partners LLC now owns 8,698 shares of the company’s stock worth $129,000 after purchasing an additional 3,008 shares during the period. Finally, Entropy Technologies LP purchased a new stake in shares of Takeda Pharmaceutical in the 1st quarter worth approximately $156,000. 9.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on TAK. Zacks Research cut shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research report on Thursday, August 21st. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Takeda Pharmaceutical in a research report on Tuesday, October 14th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Trading Down 0.2%

Shares of Takeda Pharmaceutical stock opened at $14.03 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.59 and a debt-to-equity ratio of 0.60. Takeda Pharmaceutical Co. has a 12-month low of $12.80 and a 12-month high of $15.69. The firm has a market capitalization of $44.63 billion, a price-to-earnings ratio of 46.75 and a beta of 0.21. The firm’s 50 day simple moving average is $14.75 and its two-hundred day simple moving average is $14.73.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The business had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Analysts predict that Takeda Pharmaceutical Co. will post 1.64 EPS for the current year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.